Resultados de Búsqueda por Autor

artículo

Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease

Publicado por
Arab, Juan Pablo, Dirchwolf, Melisa, Álvares-da-Silva, Mário Reis, Barrera, Francisco, Benítez, Carlos, Castellanos-Fernandez, Marlene, Castro-Narro, Graciela, Chavez-Tapia, Norberto, Chiodi, Daniela, Cotrim, Helma, Cusi, Kenneth, de Oliveira, Claudia Pinto Marques Souza, Díaz, Javier, Fassio, Eduardo, Gerona, Solange, Girala, Marco, Hernandez, Nelia, Marciano, Sebastián, Masson, Walter, Méndez-Sánchez, Nahum, Leite, Nathalie, Lozano, Adelina, Padilla, Martín, Panduro, Arturo, Paraná, Raymundo, Parise, Edison, Perez, Marlene, Poniachik, Jaime, Restrepo, Juan Carlos, Ruf, Andrés, Silva, Marcelo, Tagle, Martín, Tapias, Monica, Torres, Kenia, Vilar-Gomez, Eduardo, Costa Gil, José Eduardo, Gadano, Adrian, Arrese, Marco

Publicado 2020

Enlace

Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20–30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociación Latinoamericana para el Estudio del Hígado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic F...

artículo

OP-4 Implementation of a re-linkage to care strategy in patients with chronic hepatitis c who were lost to follow-up in Latin America

Publicado por
Mendizabal, Manuel, Thompson, Marcos, Gonzalez Ballerga, Esteban, Anders, Margarita, Castro Narro, Graciela E., Pessoa, Mario G, Cheinquer, Hugo, Mezzano, Gabriel, Palazzo, Ana, Ridruejo, Ezequiel, Descalzi, Valeria, Velarde-Ruiz Velasco, Jose A., Marciano, Sebastian, Muñoz, Linda, Schinoni, Maria I., Poniachik, Jaime, Perazzo, Rosalía, Cerda, Eira, Fuster, Francisco, Varon, Adriana, García Ruiz, Sandro, Soza, Alejandro, Cabrera, Cecilia, Gomez Aldana, Andres J, Beltrán, Flor de María, Gerona, Solange, Cocozzella, Daniel, Bessone, Fernando, Hernández, Nelia, Alonso, Cristina, Ferreiro, Melina, Antinucci, Florencia, Torre, Aldo, Moutinho, Bruna D., Borges, Silvia Coelho, Gomez, Fernando, Murga, Maria Dolores, Piñero, Federico, Sotera, Gisela F, Ocampo, Jhonier A., Mollinedo, Valeria A Cortés, Girala, Marcos, Montes, Pedro, Ratusnu, Natalia, Zuñagua, Claudia A., Castillo, Lida, Barradas, Mauricio Castillo, Chávez, Rocío, Ivantes, Cláudia, Brutti, Julia, Tenorio, Laura, Garavito, Jorge, Zevallos, Katherine, Contreras, Fernando, Infante, Mirtha, Vera-Pozo, Emilia, Tagle, Martín, Toro, Luis G., De La Rocha, Carlos A., Simian, Daniela, Silva, Marcelo O.

Publicado 2023

Enlace

Aproximadamente 1 de cada 4 pacientes con VHC crónico que eran LTFU eran candidatos para recibir tratamiento. Esta estrategia tiene el potencial de ser efectiva y accesible y tiene un impacto significativo en la cascada de atención del VHC.